Helen Sabzevari - Jan 4, 2022 Form 4 Insider Report for PRECIGEN, INC. (PGEN)

Role
President and CEO, Director
Signature
/s/ Helen Sabzevari, by Donald P. Lehr, as attorney-in-fact
Stock symbol
PGEN
Transactions as of
Jan 4, 2022
Transactions value $
-$24,987
Form type
4
Date filed
1/6/2022, 04:08 PM
Previous filing
Jan 4, 2022
Next filing
Feb 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PGEN Common Stock Options Exercise +17.7K +2.44% 741K Jan 4, 2022 Direct F1
transaction PGEN Common Stock Sale -$4.87K -1.36K -0.18% $3.59 740K Jan 5, 2022 Direct F2
transaction PGEN Common Stock Sale -$20.1K -5.6K -0.76% $3.59 734K Jan 5, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PGEN Restricted Stock Units Options Exercise $0 -17.7K -50% $0.00 17.7K Jan 4, 2022 Common Stock 17.7K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
F2 This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of RSUs.
F3 The RSUs were granted on January 4, 2019 and January 25, 2019 and the remaining RSUs vest on January 4, 2023.